Role of Genomics in Identifying Biomarkers for Response and Resistance to Anti-Cancer Immunotherapy

July 28, 2017

Dr Eliezer Van Allen, Assistant Professor at Harvard Medical School and Medical Oncologist at the Dana Farber Cancer Institute, discusses his groundbreaking work in the genomics of cancer immunotherapy. He highlights how next-generation sequencing (NGS) can identify biomarkers of response and resistance to immunotherapy, and can determine how cancers develop resistance to immune checkpoint blockade.

Explore cancer immunotherapy research and relevant publications here.

View related videos:

Subscribe to the Illumina video channel

For Research Use Only. Not for use in diagnostic procedures.

Share this article on